INM (InMed Pharmaceuticals) 3-Year Revenue Growth Rate : 0.00% (As of Sep. 2024)

View and export this data going back to . Start your Free Trial

What is InMed Pharmaceuticals 3-Year Revenue Growth Rate?

InMed Pharmaceuticals's Revenue per Share for the three months ended in Sep. 2024 was $40.81.

During the past 12 months, InMed Pharmaceuticals's average Revenue per Share Growth Rate was -64.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of InMed Pharmaceuticals was -12.20% per year. The lowest was -63.40% per year. And the median was -54.25% per year.

Competitive Comparison of InMed Pharmaceuticals's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, InMed Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InMed Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InMed Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where InMed Pharmaceuticals's 3-Year Revenue Growth Rate falls into.

InMed Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

InMed Pharmaceuticals (NAS:INM) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

InMed Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (NAS:INM) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

MWG:Germany MWG:Germany

Address

885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.

Executives

Mancini Alexandra Diane Janet	officer: Sr VP, Clinical Reg Affairs	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Andrew Hull	director	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Eric A Adams	director, officer: President & CEO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Jonathan Tegge	officer: Interim CFO	217 W. MAIN STREET, SOMERVILLE NJ 08876
Sarah Li	officer: VP, Accounting and Controller	310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Bryan T Baldasare	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Brenda Edwards	officer: Interim CFO	111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2
Janet P Grove	director	510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5
Bruce Colwill	officer: CFO	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4
Shane Aaron Johnson	officer: SVP & GM of BayMedica LLC	930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451
Adam D. Cutler	director	9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729
William J Garner	director	875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010
Catherine Sazdanoff	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric C Hsu	officer: Sr. VP, Pre-Clinical Res/Dev	C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4